Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of dose-modification strategy for azacitidine + venetoclax in AML patients with cytopenias during remission
MOH_2020-11-15_009503Phase 2Not yet recruiting
- Sponsor
- ד"ר ישי עופרן חוקר ראשי
- Start
- Oct 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in acute myeloid leukemia (AML) comparing Reduced venetoclax duration with Reduced azacitidine duration (2 arms). Planned start Oct 2020; status: not yet recruiting.
02
Drugs
azacitidinevenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2020-11-15_009503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-11-15_009503.